^
    5ms
    Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer (clinicaltrials.gov)
    P1/2, N=27, Not yet recruiting, Fred Hutchinson Cancer Center
    New P1/2 trial
    |
    Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv) • quemliclustat (AB680)
    5ms
    Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2- breast cancer: a randomized phase 2 trial. (PubMed, Nat Med)
    These findings suggest that iSBRT + anti-PD-L1 may convert immune-cold ER+HER2- BC into more inflamed tumors and improve response, particularly in PD-L1-negative disease. ClinicalTrials.gov registration: NCT03875573 .
    P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    PD-L1 expression • ER positive • HER-2 negative • PD-L1 negative • HER-2 negative + ER positive
    |
    MammaPrint®
    |
    Imfinzi (durvalumab) • oleclumab (MEDI9447)
    5ms
    DOSa: Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma (clinicaltrials.gov)
    P2, N=75, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    Imfinzi (durvalumab) • oleclumab (MEDI9447)
    5ms
    CHANCES: A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=27, Active, not recruiting, Institut Paoli-Calmettes | Recruiting --> Active, not recruiting
    Enrollment closed • First-in-human
    |
    PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA (Breast cancer early onset)
    |
    PD-L1 expression • HER-2 positive • HER-2 amplification • HER-2 expression • BRCA mutation • PD-L1 expression + HER-2 overexpression
    |
    Herceptin (trastuzumab) • paclitaxel • IPH5301
    5ms
    PACIFIC-9: A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=1051, Active, not recruiting, AstraZeneca | Trial primary completion date: Jun 2026 --> Sep 2026
    Trial primary completion date • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    EGFR wild-type • ALK wild-type
    |
    Imfinzi (durvalumab) • oleclumab (MEDI9447) • monalizumab (IPH2201)
    5ms
    SPRINT 2: The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2 (clinicaltrials.gov)
    P2, N=52, Not yet recruiting, Montefiore Medical Center | Trial completion date: Oct 2028 --> Feb 2029 | Initiation date: May 2026 --> Sep 2026 | Trial primary completion date: Dec 2027 --> Apr 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Imfinzi (durvalumab) • oleclumab (MEDI9447) • monalizumab (IPH2201)
    6ms
    Glycerol-mediated nose-to-brain codelivery of anti-IL-17 and anti-CD73 antibodies enhances immunotherapy for melanoma brain metastases. (PubMed, Sci Adv)
    Ultimately, this combination promoted CD8+ T cell activation and residency, pro-inflammatory macrophage polarization, and reduced Treg cell infiltration, thereby eliciting a strong antitumor effect. Our results establish an efficient nose-to-brain delivery platform for macromolecules and propose a therapeutic strategy for tumors using anti-IL-17 to overcome TME-imposed limitations in CD73-targeted immunotherapy.
    Journal
    |
    CD8 (cluster of differentiation 8) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • IL17A (Interleukin 17A)
    6ms
    A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA) (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, AstraZeneca | Trial completion date: Jun 2027 --> Mar 2027
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    EGFR wild-type • ALK wild-type
    |
    Imfinzi (durvalumab) • oleclumab (MEDI9447)
    6ms
    A Phase I/II Study of TJ004309 for Advanced Solid Tumor (clinicaltrials.gov)
    P1/2, N=225, Completed, TJ Biopharma Co., Ltd. | Active, not recruiting --> Completed | N=376 --> 225
    Trial completion • Enrollment change • IO biomarker
    |
    Loqtorzi (toripalimab-tpzi) • uliledlimab (TJD5)
    6ms
    Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24) (clinicaltrials.gov)
    P1, N=8, Completed, Arcus Biosciences, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    quemliclustat (AB680)
    7ms
    Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases (clinicaltrials.gov)
    P2, N=24, Recruiting, Weill Medical College of Cornell University | Trial completion date: Mar 2027 --> Dec 2027 | Trial primary completion date: Sep 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    MSI (Microsatellite instability)
    |
    balstilimab (AGEN2034) • botensilimab (AGEN1181) • dalutrafusp alfa (AGEN1423)
    8ms
    CHANCES: A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=27, Recruiting, Institut Paoli-Calmettes | Trial completion date: Feb 2026 --> Mar 2027 | Trial primary completion date: Mar 2025 --> Mar 2027
    Trial completion date • Trial primary completion date • First-in-human
    |
    PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA (Breast cancer early onset)
    |
    PD-L1 expression • HER-2 positive • HER-2 amplification • HER-2 expression • BRCA mutation • PD-L1 expression + HER-2 overexpression
    |
    Herceptin (trastuzumab) • paclitaxel • IPH5301